MitoSciences has patent pending tests for measuring pyruvate dehydrogenase (PDH) activity in both high-throughput and clinical platforms, and intends to use the newly accessed proteins to provide complete solutions for understanding the activity of PDH.
The new products that will soon be released by MitoSciences are expected to allow drug developers to quickly and accurately screen potential PDH kinase inhibitors.
Jean-Paul Audette, president of MitoSciences, said: “MitoSciences has been at the leading edge in designing novel tools for measuring PDH. And with the combination of our existing technology and the new proteins from Hospital for Sick Children (SickKids) we can now provide the most complete solution available anywhere for understanding PDH and its activity in human and rodent cells.”